Coronavirus Update: Japan Approves Sotrovimab
Plus, Indian Trial For Novavax/Serum Vaccine
Executive Summary
Japan approves a second antibody therapy for COVID-19 in short order, while India gives the go-ahead to a local clinical program for Novavax/Serum Institute's recombinant protein vaccine candidate.
You may also be interested in...
APAC Podcast: Policies Play Out Against Pandemic, Corporate Activity Remains Strong
Join the Asia Pacific content team for a wide-ranging overview and analysis of recent developments across China, India, South Korea and Japan in the policy, regulatory, commercial and vaccines spaces over the past few months.
APAC Podcast: Policies Play Out Against Pandemic, Corporate Activity Remains Strong
Join the Asia Pacific content team for a wide-ranging overview and analysis of recent developments across China, India, South Korea and Japan in the policy, regulatory, commercial and vaccines spaces over the past few months.
Biocon Buoyant On ‘Unique Positioning’ Of Partnered COVID-19 Antibody
Biocon management signals the potential of its partnered entry with Serum Institute and Adagio Therapeutics into the communicable diseases segment. Continuing large supply opportunities for COVID-19 vaccines and prospects for boosters, alongside the promising profile of the neutralizing antibody being developed by its US-based partner, also bode well.